XML 44 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
SEGMENT AND ENTERPRISE-WIDE INFORMATION
 12 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
SEGMENT AND ENTERPRISE-WIDE INFORMATION
SEGMENT AND ENTERPRISE-WIDE INFORMATION
We determine our reportable segments by first identifying our operating segments and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics.
The Company’s reportable segments are as follows:
•
Japan
•
EMEA
•
North America Plasma
•
All Other
The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.
Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, asset impairments and legal charges. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.
During the first quarter of fiscal 2018, management changed the cost reporting structure such that a portion of corporate expenses were reclassified into the operating segments. Accordingly, the prior year numbers have been updated to reflect this reclassification.
Selected information by business segment is presented below:
(In thousands)
2018
 
2017
 
2016
Net revenues
 
 
 
 
 
Japan
$
68,172

 
$
74,695

 
$
84,270

EMEA
183,301

 
198,396

 
204,192

North America Plasma
333,831

 
309,718

 
279,803

All Other
324,013

 
316,771

 
342,249

Net revenues before foreign exchange impact
909,317

 
899,580

 
910,515

Effect of exchange rates
(5,394
)
 
(13,464
)
 
(1,683
)
Net revenues
$
903,923

 
$
886,116

 
$
908,832

(In thousands)
2018
 
2017
 
2016
Segment operating income
 
 
 
 
 
Japan
$
37,243

 
$
39,892

 
$
43,619

EMEA
62,696

 
65,689

 
63,665

North America Plasma
119,003

 
98,254

 
109,220

All Other
128,945

 
127,834

 
127,493

Segment operating income
347,887

 
331,669

 
343,997

  Corporate operating expenses
(220,699
)
 
(211,481
)
 
(227,839
)
  Effect of exchange rates
4,059

 
(4,772
)
 
3,546

Restructuring and turnaround costs
(44,125
)
 
(34,337
)
 
(42,185
)
Deal amortization
(26,013
)
 
(27,107
)
 
(28,958
)
Impairment of assets
(1,941
)
 
(73,353
)
 
(97,230
)
Legal charges(1)
(3,011
)
 
—

 
—

Contingent consideration income
—

 
—

 
4,727

Operating income (loss)
$
56,157

 
$
(19,381
)
 
$
(43,942
)
(1) Reflects net impact of settlement charges associated with the fiscal 2017 voluntary whole blood collection kits recall.
(In thousands)
2018
 
2017
 
2016
Depreciation and amortization
 
 
 
 
 
Japan
$
486

 
$
827

 
$
774

EMEA
4,464

 
4,255

 
5,146

North America Plasma
16,060

 
13,022

 
12,944

All Other
68,237

 
71,629

 
71,047

Total depreciation and amortization (excluding impairment charges)
$
89,247

 
$
89,733

 
$
89,911

(In thousands)
March 31,
2018
 
April 1,
2017
 
April 2,
2016
Long-lived assets(2)
 
 
 
 
 
Japan
$
26,640

 
$
21,412

 
$
33,159

EMEA
74,783

 
63,854

 
63,861

North America Plasma
91,815

 
142,164

 
116,001

All Other
138,918

 
96,432

 
124,613

Total long-lived assets
$
332,156

 
$
323,862

 
$
337,634

(2) Long-lived assets are comprised of property, plant and equipment.
Selected information by principle operating regions is presented below:
(Dollars in thousands)
2018
 
2017
 
2016
Net Revenues
 
 
 
 
 
United States
$
548,731

 
$
522,686

 
$
519,440

Japan
67,319

 
79,266

 
81,411

Europe
164,226

 
166,007

 
187,725

Asia
115,127

 
109,858

 
111,758

Other
8,520

 
8,299

 
8,498

Net revenues
$
903,923

 
$
886,116

 
$
908,832

(Dollars in thousands)
March 31,
2018
 
April 1,
2017
 
April 2,
2016
Long-lived assets(2)
 
 
 
 
 
United States
$
236,603

 
$
241,610

 
$
231,744

Japan
1,511

 
1,691

 
2,022

Europe
13,696

 
12,952

 
18,672

Asia
36,431

 
34,174

 
40,235

Other
43,915

 
33,435

 
44,961

Total long-lived assets
$
332,156

 
$
323,862

 
$
337,634

(2) Long-lived assets are comprised of property, plant and equipment.

Our products are organized into four categories for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units, however, no other financial information is currently available on this basis.
Net revenues by business unit are as follows:
(Dollars in thousands)
2018
 
2017
 
2016
Plasma
435,956

 
410,727

 
381,776

Blood Center
284,902

 
303,890

 
355,108

Cell Processing
107,562

 
105,376

 
112,483

Hemostasis Management
75,503

 
66,123

 
59,465

Net revenues
$
903,923

 
$
886,116

 
$
908,832